TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07249346: Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blo

Sponsor: Hannah Choe, MD · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 124 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07249346 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07249346 Rescue Dossier →